What is PT-141 Peptide?
14September 14, 2022
What is PT-141 Peptide for Sexual Arousal?
PT-141, also known as bremelanotide, is a synthetic melanocortin receptor agonist investigated as a potential research compound for studying hypoactive sexual desire mechanisms. It is also being investigated for its potential to treat erectile dysfunction by uniquely influencing arousal pathways through targeting neural receptors rather than vascular systems in laboratory models.
PT-141 is available in lyophilized powder form and offered in 10 mg vials for research applications.
At Loti Labs, we pride ourselves on stocking high-quality research compounds. Our PT-141 is available for research purposes only and not intended for any applications outside laboratory settings.
Definition and explanation of PT-141 peptide
PT-141, also known as bremelanotide, is a synthetic peptide that has garnered significant interest in research contexts for its potential mechanisms related to sexual function in various research models. As a novel sexual dysfunction agent and melanocortin receptor agonist, laboratory studies suggest PT-141 interacts with specific neural receptors, which may influence arousal pathways and reproductive behaviors in research specimens. Unlike other compounds that primarily affect vascular parameters, PT-141 appears to target the nervous system, making it an intriguing subject for scientific investigation. In laboratory settings, researchers have administered this compound via various methods to examine its effects on reproductive behaviors in animal models, offering potentially valuable insights for ongoing scientific inquiry in this field.
Brief history of PT-141 peptide research
The investigation of PT-141 began in the 1990s when researchers initially explored its mechanisms in laboratory settings. Early findings suggested interesting properties that shifted the research focus toward understanding arousal pathways. This led to extensive experimental protocols and analyses aimed at examining reproductive behaviors in various research models. Over the years, PT-141 has undergone rigorous scientific investigation to better understand its mechanisms and potential applications in research settings. These studies have contributed valuable insights to our understanding of neural pathways involved in reproductive behaviors and continue to inform ongoing scientific inquiry.
What Is PT-141 (Bremelanotide) and How Does It Work for Female Sexual Dysfunction?
PT-141 is a synthetic seven amino acid peptide investigated in laboratory settings as a research compound for studying sexual function mechanisms in premenopausal women and animal models.
While conducting research with PT-141 in male rats and non-human primates, scientists documented interesting physiological responses. The findings suggest that PT-141 may represent a novel approach for investigating sexual function mechanisms. Research indicates that PT-141 appears to influence both neural pathways and vascular parameters in laboratory specimens.
STRUCTURE OF PT-141
Molecular Formula: C50H68N14O10
Molecular weight: 1025.2 g/mol
CAS number: 189691-06-3
IUPAC name: (3S,6S,9R,12S,15S,23S)-15-[[(2S)-2-acetamidohexanoyl]amino]-9-benzyl-6-[3-(diaminomethylideneamino)propyl]-12-(1H-imidazol-5-ylmethyl)-3-(1H-indol-3-ylmethyl)-2,5,8,11,14,17-hexaoxo-1,4,7,10,13,18-hexazacyclotricosane-23-carboxylic acid
MECHANISM OF ACTION
PT-141 functions as an agonist of various melanocortin receptors, which in order of potency are MC1R, MC4R, MC3R, MC5R, and MC2R. The precise mechanism by which PT-141 influences reproductive behavior pathways in research models remains under investigation.
One theory suggests that PT-141 may stimulate dopamine production in the medial preoptic area, a region involved in the reproductive behaviors of several organisms in laboratory settings. Additionally, research indicates that PT-141 appears to influence vascular parameters in experimental models, potentially enhancing physiological responses related to reproductive function. Unlike traditional treatments that target the vascular system to help achieve an erection, PT-141 operates through neural pathways, highlighting its unique mechanism of enhancing sexual desire.
Benefits of PT-141 Peptide
Investigating Hypoactive Sexual Desire Mechanisms
PT-141 is being studied to better understand the underlying mechanisms of reproductive behavior in laboratory models. Research suggests that PT-141 may provide valuable insights into the neural pathways associated with arousal responses. In controlled laboratory settings, PT-141 has demonstrated interesting effects on behavioral and physiological parameters in research specimens. By examining these responses, researchers aim to expand our understanding of complex neural circuitry involved in reproductive functions, potentially contributing to broader scientific knowledge in this field.
Exploring Sexual Function and Desire Pathways
Beyond basic mechanistic studies, research suggests PT-141 may offer insights into both neural and vascular components of reproductive function. PT-141 has shown potential to improve sexual performance by enhancing both neural and vascular components. Laboratory findings indicate potential influences on blood flow parameters in research specimens, which may affect physiological responses related to reproductive behaviors. This vascular component appears important in various experimental models for maintaining optimal tissue function. Ongoing research with PT-141 continues to explore its unique mechanism of action, which targets neural pathways rather than focusing solely on vascular effects, offering a fascinating avenue for scientific investigation.
PT-141 Peptide EFFECTS on Erectile Function Research
Research suggests that PT-141 is being researched for its potential to treat sexual dysfunction in laboratory specimens and may produce the following observations:
Potentially prolonged vascular responses
Possible alterations in performance parameters
Potential influence on urinary tract muscle tone
Metabolic parameter changes
Cardiovascular parameter alterations
Stress response modifications
Research protocols should include appropriate monitoring measures, particularly in specimens with altered blood pressure parameters, to properly assess physiological responses.
PT-141 OBSERVED RESPONSES
Research has documented the following responses in laboratory settings:
Cutaneous flushing
Cranial discomfort
Gastrointestinal disturbances
Localized reactions at administration sites
Respiratory responses
Energy level alterations
Sensory changes
Balance disruptions
Respiratory tract congestion
Pigmentation changes
Research protocols should include monitoring for high blood pressure in specimens.
Potential Drawbacks of PT-141
While PT-141 has shown promise in treating sexual dysfunction, there are potential drawbacks to consider. One of the main concerns is the risk of increased blood pressure, which can be particularly problematic for individuals with pre-existing hypertension. This side effect necessitates careful monitoring and may limit the use of PT-141 in certain populations.
Additionally, PT-141 may cause darkening of the gums, face, and breasts, which, although not harmful, can be a cosmetic issue for some individuals. This pigmentation change is a result of the peptide’s action on melanocortin receptors, which are involved in skin pigmentation.
Other common side effects include nausea, pain at the site of injection, and headaches. These symptoms can be uncomfortable and may deter some users from continuing treatment. It is also important to note that PT-141 is not approved for use in postmenopausal women or men, and its effectiveness in these populations is not well established. This limitation underscores the need for further research to fully understand the peptide’s potential and safety profile.
The Future of PT-141 Research
Research on PT-141 is ongoing, and there are several promising areas of investigation that could lead to new treatments for sexual dysfunction. One exciting avenue is the potential use of PT-141 in combination with other medications to enhance its effects. For instance, combining PT-141 with a phosphodiesterase type 5 (PDE5) inhibitor, such as sildenafil (Viagra), may enhance its ability to increase blood flow and improve sexual function. This combination therapy could offer a more comprehensive approach to treating sexual dysfunction.
Another area of research is the development of new delivery systems for PT-141. Current administration methods, such as injections, can be inconvenient and uncomfortable for some users. Researchers are exploring oral and transdermal formulations, which could make the medication more user-friendly and increase patient compliance.
Additionally, the potential therapeutic uses of PT-141 are being expanded beyond sexual dysfunction. Preliminary studies suggest that PT-141 may have applications in treating conditions such as obesity and depression. These potential new uses could significantly broaden the scope of PT-141’s therapeutic benefits and provide new avenues for treatment.
Overall, the future of PT-141 research holds great promise. Continued investigation into combination therapies, new delivery systems, and expanded therapeutic uses could lead to significant advancements in the treatment of sexual dysfunction and other conditions, improving the quality of life for many individuals.
LOOKING FOR WHERE TO BUY PT-141 ONLINE
When searching for research compounds online, it is paramount to source from a trusted laboratory to ensure the integrity of your scientific investigations.
Loti Labs offers competitive pricing with comprehensive quality control documentation. We provide thorough technical support and a comprehensive return policy for our research materials.
Visit our website or contact us today to acquire PT-141 for your research applications.
References:
Clayton AH, Lucas J, DeRogatis LR, Jordan R. Phase I randomized placebo-controlled, double-blind study of the safety and tolerability of bremelanotide coadministered with ethanol in healthy male and female participants. Clin Ther. 2017;39:514–526.e14. [PubMed]
Bremelanotide (Vyleesi) for hypoactive sexual desire disorder. Med Lett Drugs Ther. 2019;61(1577):114–6. [PubMed]
Dhillon S, Keam SJ. Bremelanotide: First Approval. Drugs. 2019;79:1599–606. [PubMed]
Kingsberg SA, Clayton AH, Portman D, Williams LA, Krop J, Jordan R, Lucas J, et al. Bremelanotide for treating hypoactive sexual desire disorder: two randomized phase 3 trials. Obstet Gynecol. 2019;134:899–908. [PMC free article] [PubMed]
Simon JA, Kingsberg SA, Portman D, Williams LA, Krop J, Jordan R, Lucas J, et al. Long-term safety and efficacy of bremelanotide for hypoactive sexual desire disorder. Obstet Gynecol. 2019;134:909–17. [PMC free article] [PubMed]
